Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Secondary Hyperparathyroidism peptide trials
8 selected ClinicalTrials.gov records carrying the official condition label Secondary Hyperparathyroidism. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
8 selected records.
2 profiles.
2017–2026 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 90 selected PubMed records and 8 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Secondary Hyperparathyroidism unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT01254565
PeptideScanner retained ClinicalTrials.gov record NCT01254565 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was etelcalcetide.
- PeptideScanner change date
- November 15, 2026
- Cited source date
- April 13, 2017
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT01414114
PeptideScanner retained ClinicalTrials.gov record NCT01414114 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was etelcalcetide.
- PeptideScanner change date
- November 15, 2026
- Cited source date
- April 11, 2017
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT01896232
PeptideScanner retained ClinicalTrials.gov record NCT01896232 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-07-18, and PeptideScanner's reviewed identity mapping was etelcalcetide.
- PeptideScanner change date
- November 15, 2026
- Cited source date
- July 18, 2019
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Etelcalcetide · 2026-08-21
ClinicalTrials.gov record NCT03969329
Recruiting at the retained observation.
Open attributed record →Etelcalcetide · 2026-02-27
ClinicalTrials.gov record NCT03633708
Recruiting at the retained observation.
Open attributed record →Teriparatide · 2022-11-10
ClinicalTrials.gov record NCT04750460
Completed at the retained observation.
Open attributed record →Etelcalcetide · 2021-04-30
ClinicalTrials.gov record NCT03299244
Completed at the retained observation.
Open attributed record →Etelcalcetide · 2020-02-10
ClinicalTrials.gov record NCT03283098
Completed at the retained observation.
Open attributed record →Etelcalcetide · 2019-07-18
ClinicalTrials.gov record NCT01896232
Completed at the retained observation.
Open attributed record →Etelcalcetide · 2017-04-13
ClinicalTrials.gov record NCT01254565
Completed at the retained observation.
Open attributed record →Etelcalcetide · 2017-04-11
ClinicalTrials.gov record NCT01414114
Completed at the retained observation.
Open attributed record →